Tissue factor and fibrin in tumor angiogenesis

Area of Science:

• Oncology
• Hematology
• Vascular Biology

Background:

• Cancer patients often exhibit hypercoagulability, leading to complications like venous thromboembolism (VTE).
• Tissue factor (TF), the coagulation initiator, is abnormally expressed in tumors, promoting clot formation and angiogenesis.
• TF-mediated clotting contributes to tumor growth, metastasis, and VTE, a known complication of antiangiogenic therapies.

Purpose of the Study:

• To elucidate the role of tissue factor (TF) in cancer-associated hypercoagulability, tumor angiogenesis, and metastasis.
• To investigate TF's contribution to venous thromboembolism (VTE) in cancer patients, particularly those undergoing antiangiogenic therapy.
• To evaluate TF as a potential therapeutic target for cancer treatment and prevention of associated thromboembolic complications.

Main Methods:

• Review of literature on tissue factor's role in cancer pathophysiology.
• Analysis of mechanisms linking TF to coagulation, angiogenesis, and metastasis.
• Discussion of TF's involvement in VTE associated with antiangiogenic agents.

Main Results:

• TF is a key mediator of cancer-associated hypercoagulability, promoting VTE and tumor angiogenesis through both clotting-dependent and -independent pathways.
• TF-induced thrombin generation and fibrin deposition create a proangiogenic matrix, facilitating tumor vascularization.
• TF activation is implicated in VTE complications arising from combined chemotherapy and antiangiogenic treatments.

Conclusions:

• Tissue factor plays a critical role in the pathogenesis of cancer, driving hypercoagulability, angiogenesis, and metastasis.
• Targeting TF presents a promising therapeutic strategy to combat cancer progression and mitigate thromboembolic complications.
• Anticoagulants like low-molecular-weight heparin may offer dual benefits by inhibiting TF-mediated clotting and angiogenesis.